Achillion, a wholly owned subsidiary of Alexion
28
0
0
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
2 terminated/withdrawn out of 28 trials
92.9%
+6.4% vs industry average
0%
0 trials in Phase 3/4
31%
8 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (28)
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
Role: collaborator
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Role: collaborator
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Role: collaborator
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
Role: collaborator
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
Role: collaborator
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
Role: collaborator
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
Role: collaborator
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Role: collaborator
A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: collaborator
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
Role: collaborator
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: collaborator
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
Role: collaborator
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Role: collaborator
A Study of Single-dose ALXN2050 in Healthy Adults
Role: collaborator
A Study of Multiple Doses of ALXN2050 in Healthy Adults
Role: collaborator
A Study of the Cardiac Effects of Danicopan in Healthy Adults
Role: collaborator
A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
Role: collaborator
Study of Danicopan in Participants With Hepatic Impairment
Role: collaborator
Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
Role: collaborator
A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
Role: collaborator